A novel complex [Zn（Im）2（A-glu）]-0.5H2O（Im = imidazole, A-glu = N-acetyi- L-glutamic acid） has been synthesized from the reaction of A-glu with Zn（CH3COO）2·2H20 in the presence of Im at 65 ℃, and structu...A novel complex [Zn（Im）2（A-glu）]-0.5H2O（Im = imidazole, A-glu = N-acetyi- L-glutamic acid） has been synthesized from the reaction of A-glu with Zn（CH3COO）2·2H20 in the presence of Im at 65 ℃, and structurally characterized by single-crystal X-ray diffraction. The complex crystallizes in tetragonai, space group P43212 with a = b = 8.9078（6）, c = 43.458（6） A, C26H36N10O11Zn2, Mr = 795.39, V= 3448.3（6） A^3, De = 1.532 g/cm^3, Z = 4,μ（MoKα） = 1.461 mm^-1, F（000） = 1640, the final R = 0.0453 and wR = 0.0992. X-ray analysis reveals that the crystal structure is constructed by mixed iigands. A-glu adopts the bis-monodentate coordination mode linking two adjacent metal ions to form a one-dimensional chain. Zinc（Ⅱ） ions are four-coordinated with a distorted tetrahedral geometry. Luminescent properties of the complex have been inves- tigated.展开更多
Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after t...Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after the first-line chemoradiotherapy. Methods: The data of 67 LS-SCLC patients who received combined treatment of Chinese medicine(CM) and Western medicine(WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method(Kaplan–Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time. Results: The median PFS in the CM and WM combination treatment group and the WM group were 19 months(95% CI: 12.36–25.64) vs. 9 months(95% CI: 5.96–12.04), respectively, HR=0.43(95% CI: 0.27–0.69, P <0.001). The median OS in the CM and WM combination group and the WM group were 34.00 months(95% CI could not be calculated) vs. 18.63 months(95% CI: 16.43–20.84), respectively, HR=0.40(95% CI: 0.24–0.66, P<0.001). Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months(P<0.001). Conclusion: The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone.(Registration No. Chi CTR2200056616)展开更多
目的探讨阿利沙坦酯片联合肾炎康复片治疗糖尿病肾病合并轻-中度高血压患者的临床疗效,为糖尿病肾病的治疗提供依据。方法选择2017年10月至2018年10月天津市中医药研究院附属医院收治的84例糖尿病肾病Ⅳ期合并轻-中度高血压患者作为研...目的探讨阿利沙坦酯片联合肾炎康复片治疗糖尿病肾病合并轻-中度高血压患者的临床疗效,为糖尿病肾病的治疗提供依据。方法选择2017年10月至2018年10月天津市中医药研究院附属医院收治的84例糖尿病肾病Ⅳ期合并轻-中度高血压患者作为研究对象,按随机数字表法分为联合治疗组和对照组。对照组在常规治疗的基础上加用阿利沙坦酯片治疗,联合治疗组在对照组的基础上,联合肾炎康复片治疗。两组患者疗程均为12周。观察两组治疗前后收缩压(SBP)、舒张压(DBP)、24 h尿白蛋白排泄率(24 h UAE)、尿转铁蛋白(UTRF)、尿α1-微球蛋白(α1-MG)、尿β2-微球蛋白(β2-MG)、血清胱抑素C(Cys-C)、血肌酐(SCr)、糖化血红蛋白(HbA1C)的变化。用SPSS 23.0统计软件包进行t检验、非参数检验和χ2检验。结果两组治疗前SBP、DBP、HbA1C、SCr和Cys-C比较,差异均无统计学意义(P>0.05);两组治疗后SBP、DBP、HbA1C、SCr和Cys-C均较本组治疗前明显降低,差异均有统计学意义(P<0.01),但两组治疗后比较,差异均无统计学意义(P>0.05)。两组治疗前24 h UAE、UTRF、α1-MG和β2-MG比较,差异均无统计学意义(P>0.05);两组患者治疗后24 h UAE、UTRF、α1-MG和β2-MG明显低于本组治疗前,差异均有统计学意义(P<0.01),且联合治疗组治疗后上述指标水平均明显低于对照组治疗后,差异均有统计学意义(P<0.05,P<0.01)。结论阿利沙坦酯片联合肾炎康复片能有效控制糖尿病肾病合并轻-中度高血压患者血压,降低蛋白尿,保护肾功能。展开更多
基金This work was supported by the National Natural Science Foundation of China (No. 20471026), the Natural Science Foundation of Henan Province (No. 0311021200) and the Foundation of Education Committee of Henan Province (2006150017)
文摘A novel complex [Zn（Im）2（A-glu）]-0.5H2O（Im = imidazole, A-glu = N-acetyi- L-glutamic acid） has been synthesized from the reaction of A-glu with Zn（CH3COO）2·2H20 in the presence of Im at 65 ℃, and structurally characterized by single-crystal X-ray diffraction. The complex crystallizes in tetragonai, space group P43212 with a = b = 8.9078（6）, c = 43.458（6） A, C26H36N10O11Zn2, Mr = 795.39, V= 3448.3（6） A^3, De = 1.532 g/cm^3, Z = 4,μ（MoKα） = 1.461 mm^-1, F（000） = 1640, the final R = 0.0453 and wR = 0.0992. X-ray analysis reveals that the crystal structure is constructed by mixed iigands. A-glu adopts the bis-monodentate coordination mode linking two adjacent metal ions to form a one-dimensional chain. Zinc（Ⅱ） ions are four-coordinated with a distorted tetrahedral geometry. Luminescent properties of the complex have been inves- tigated.
基金the Science and Technology Innovation Project of the China Academy of Chinese Medical Sciences(No.CI2021A01808)the Natural Science Foundation of Beijing(No.7212189)the Outstanding Young Scientific and Technological Talents(Innovation)Training Program of China Academy of Chinese Medical Sciences(No.ZZ15-YQ-026)。
文摘Objective: To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival(PFS) and overall survival(OS) of limited-stage small-cell lung cancer(LS-SCLC) patients after the first-line chemoradiotherapy. Methods: The data of 67 LS-SCLC patients who received combined treatment of Chinese medicine(CM) and Western medicine(WM) between January 2013 and May 2020 at the outpatient clinic of Guang’anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method(Kaplan–Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time. Results: The median PFS in the CM and WM combination treatment group and the WM group were 19 months(95% CI: 12.36–25.64) vs. 9 months(95% CI: 5.96–12.04), respectively, HR=0.43(95% CI: 0.27–0.69, P <0.001). The median OS in the CM and WM combination group and the WM group were 34.00 months(95% CI could not be calculated) vs. 18.63 months(95% CI: 16.43–20.84), respectively, HR=0.40(95% CI: 0.24–0.66, P<0.001). Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months(P<0.001). Conclusion: The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone.(Registration No. Chi CTR2200056616)
文摘目的探讨阿利沙坦酯片联合肾炎康复片治疗糖尿病肾病合并轻-中度高血压患者的临床疗效,为糖尿病肾病的治疗提供依据。方法选择2017年10月至2018年10月天津市中医药研究院附属医院收治的84例糖尿病肾病Ⅳ期合并轻-中度高血压患者作为研究对象,按随机数字表法分为联合治疗组和对照组。对照组在常规治疗的基础上加用阿利沙坦酯片治疗,联合治疗组在对照组的基础上,联合肾炎康复片治疗。两组患者疗程均为12周。观察两组治疗前后收缩压(SBP)、舒张压(DBP)、24 h尿白蛋白排泄率(24 h UAE)、尿转铁蛋白(UTRF)、尿α1-微球蛋白(α1-MG)、尿β2-微球蛋白(β2-MG)、血清胱抑素C(Cys-C)、血肌酐(SCr)、糖化血红蛋白(HbA1C)的变化。用SPSS 23.0统计软件包进行t检验、非参数检验和χ2检验。结果两组治疗前SBP、DBP、HbA1C、SCr和Cys-C比较,差异均无统计学意义(P>0.05);两组治疗后SBP、DBP、HbA1C、SCr和Cys-C均较本组治疗前明显降低,差异均有统计学意义(P<0.01),但两组治疗后比较,差异均无统计学意义(P>0.05)。两组治疗前24 h UAE、UTRF、α1-MG和β2-MG比较,差异均无统计学意义(P>0.05);两组患者治疗后24 h UAE、UTRF、α1-MG和β2-MG明显低于本组治疗前,差异均有统计学意义(P<0.01),且联合治疗组治疗后上述指标水平均明显低于对照组治疗后,差异均有统计学意义(P<0.05,P<0.01)。结论阿利沙坦酯片联合肾炎康复片能有效控制糖尿病肾病合并轻-中度高血压患者血压,降低蛋白尿,保护肾功能。
